^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

asandeutertinib (TY-9591)

i
Other names: TY-9591, TY 9591
Associations
Company:
TYK Medicines
Drug class:
EGFR inhibitor
Related drugs:
Associations
20d
New P2 trial • Metastases
|
cisplatin • carboplatin • pemetrexed • asandeutertinib (TY-9591)
9ms
New P1 trial
|
itraconazole • asandeutertinib (TY-9591) • rifampicin
10ms
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (clinicaltrials.gov)
P2, N=60, Active, not recruiting, TYK Medicines, Inc | Recruiting --> Active, not recruiting
Enrollment closed
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
asandeutertinib (TY-9591)
1year
Trial completion • Metastases
|
EGFR mutation • EGFR exon 19 deletion • EGFR T790M
|
asandeutertinib (TY-9591)
1year
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects (clinicaltrials.gov)
P1, N=10, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
Enrollment open
|
asandeutertinib (TY-9591)
1year
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (clinicaltrials.gov)
P2, N=420, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • asandeutertinib (TY-9591)
over1year
New P2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • asandeutertinib (TY-9591)
over1year
TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo (AACR 2023)
Therefore, small molecules that target palmitoylation of TEAD have been explored and VT3989 (NCT04665206) and IK-930 (NCT05228015) have success to enter the clinical trials...In line with the results of the in-vitro experiments, another YAP/TEAD inhibitor TY-0536 in combination with TY-9591 significantly delay the tumor regrowth in the PC9 CDX mouse model...[Shengli Dong and Apeng Liang contributed equally to this work. Jun Li, Shengli Dong, and Apeng Liang are the corresponding authors.]
Preclinical
|
NF2 (Neurofibromin 2)
|
NF2 deletion
|
IK-930 • TY-0584 • VT3989 • asandeutertinib (TY-9591)
almost2years
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation (clinicaltrials.gov)
P1, N=126, Recruiting, TYK Medicines, Inc | Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 19 deletion • EGFR T790M
|
asandeutertinib (TY-9591)
almost2years
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • asandeutertinib (TY-9591)
over2years
New P3 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • asandeutertinib (TY-9591)
over4years
Clinical • Enrollment open
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 19 deletion • EGFR T790M
|
asandeutertinib (TY-9591)